Evidence map›Paper›PMID 36302744›Full record

ArticleCancer reports (Hoboken, N.J.)2023

Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study.

Michel Fabbro, William Jacot, Marta Jarlier, Séverine Guiu, Véronique D'Hondt, Stéphane Pouderoux, Patrice Champoiral, Chloé Janiszewski, Isabelle Nicklès

Open access · goldAbstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Michel FabbroMedical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.ORCID 0000-0003-1910-4777
William JacotMedical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Marta JarlierBiometrics Unit, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Séverine GuiuMedical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Véronique D'HondtMedical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Stéphane PouderouxMedical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Patrice ChampoiralPsycho-Oncology Unit, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Chloé JaniszewskiClinical Research Center, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Isabelle NicklèsMedical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Université de Montpellier · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcceptability and tolerance of chemotherapy on patients treated for breast cancer remain challenging. Complementary approaches such as hypnosis may have a favorable impact both at the time of announcing and during chemotherapy, due to the notorious anxiety, distress, and self-perceived dysfunction. The objective of the study was that the patients complied with at least four self-hypnosis sessions out of the six cycles of chemotherapy.

methodsThis open, prospective longitudinal study assessed feasibility of compliance to self-hypnosis during chemotherapy in an outpatients setting. Training sessions were given by a hypnotherapist. Throughout each cycle of chemotherapy, the patient had to use self-hypnosis to better control her anxiety or any difficulties. Nurses could offer help to the patient. Chemotherapy-associated side effects were evaluated through the NCI-Common Toxicity Criteria for Adverse Events v 4.03; moreover, side effects as pain, nausea, vomiting, fatigue, and anxiety were also evaluated during chemotherapy using a visual analogic scale. Health-related quality of life, emotional distress (anxiety and depression), and cancer-related fatigue were assessed (at inclusion, end of chemotherapy and 3 months later) using the EORTC QLQ-C30 and QLQ-BR23, HADS and MFI-20 questionnaires, respectively. The number of patients screened and actually included in the study was reported, as the reasons for refusal.

resultsThirty-five patients were included with a median age of 55 years (35-78). All patients received a hypnosis training session. The overall compliance with self-hypnosis was 68.6% (95% CI: 50.7%-83.2%), meaning that more than two thirds of patients performed at least four sessions of self-hypnosis. According to NCI-CTCAE, Grade 2 nausea and vomiting was observed in 45.7% and 22.9%, respectively, Grade 2 fatigue in 62.9%. Based on the HADS questionnaire, anxiety increased at the end of the chemotherapy and returned to the initial value 3 months later (p = .97) whereas depression significantly decrease 3 months after the end of chemotherapy with respect to the inclusion (p = .003). Role, emotional, and cognitive functioning were slightly affected throughout the treatment, in contrast to dyspnea or physical functioning.

conclusionOur study showed that self-hypnosis was feasible on patients newly diagnosed for breast cancer receiving chemotherapy.

Indexed as

Breast NeoplasmsHypnosisAdultAgedChemotherapy, AdjuvantFatigueFeasibility StudiesFemaleHumansLongitudinal StudiesMiddle AgedProspective StudiesQuality of Lifealternative medicinebreast cancerchemotherapy

Identifiers

PMID36302744
PMCPMC9875600
OpenAlexW4307436800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.